PURPOSE: A single nucleotide polymorphism (-938C/A, rs2279115) was found in the bcl2 gene, whose -938A allele is significantly associated with increased Bcl2 expression compared with that of the C allele. Bcl2 up-regulation was reported to be associated with longer survival in patients with renal cancer. However, to our knowledge there is currently no information on the role of the bcl2-938C/A single nucleotide polymorphism in renal cell carcinoma cases. Therefore, we investigated the polymorphism at the bcl2 -938C/A site and its effects on clinical characteristics in patients with renal cell carcinoma. MATERIALS AND METHODS: We genotyped the bcl2-938C/A single nucleotide polymorphism in 216 patients with renal cancer, and in 209 healthy age and gender matched controls. We also investigated the relationship between the bcl2 -938C/A polymorphism, Bcl2 expression, proliferation and apoptosis status in renal cell carcinoma tissues using immunohistochemistry and TUNEL assay. The association of the bcl2 -938C/A single nucleotide polymorphism with survival in patients with renal cell carcinoma was also analyzed by Kaplan-Meier curves. RESULTS: Survival in Bcl2 positive cases was significantly longer than in negative cases. On univariate and multivariate analyses the bcl2 -938CC genotype was independently associated with poor prognosis. Kaplan-Meier analysis showed that survival in patients with CC genotypes was significantly worse than in those with CA+AA genotypes. CC genotype carriers had significantly lower Bcl2 expression and higher proliferative activity in renal cancer tissues than CA+AA genotype carriers. CONCLUSIONS: To our knowledge this is the first report to show that the bcl2 -938C/C genotype has worse prognosis and lower survival in patients with renal cell carcinoma. In addition, the bcl2 -938C/A single nucleotide polymorphism was shown to be an independent adverse prognostic factor for renal cell carcinoma.
PURPOSE: A single nucleotide polymorphism (-938C/A, rs2279115) was found in the bcl2 gene, whose -938A allele is significantly associated with increased Bcl2 expression compared with that of the C allele. Bcl2 up-regulation was reported to be associated with longer survival in patients with renal cancer. However, to our knowledge there is currently no information on the role of the bcl2-938C/A single nucleotide polymorphism in renal cell carcinoma cases. Therefore, we investigated the polymorphism at the bcl2-938C/A site and its effects on clinical characteristics in patients with renal cell carcinoma. MATERIALS AND METHODS: We genotyped the bcl2-938C/A single nucleotide polymorphism in 216 patients with renal cancer, and in 209 healthy age and gender matched controls. We also investigated the relationship between the bcl2-938C/A polymorphism, Bcl2 expression, proliferation and apoptosis status in renal cell carcinoma tissues using immunohistochemistry and TUNEL assay. The association of the bcl2-938C/A single nucleotide polymorphism with survival in patients with renal cell carcinoma was also analyzed by Kaplan-Meier curves. RESULTS: Survival in Bcl2 positive cases was significantly longer than in negative cases. On univariate and multivariate analyses the bcl2 -938CC genotype was independently associated with poor prognosis. Kaplan-Meier analysis showed that survival in patients with CC genotypes was significantly worse than in those with CA+AA genotypes. CC genotype carriers had significantly lower Bcl2 expression and higher proliferative activity in renal cancer tissues than CA+AA genotype carriers. CONCLUSIONS: To our knowledge this is the first report to show that the bcl2 -938C/C genotype has worse prognosis and lower survival in patients with renal cell carcinoma. In addition, the bcl2-938C/A single nucleotide polymorphism was shown to be an independent adverse prognostic factor for renal cell carcinoma.
Authors: J Javid; R Mir; M Mirza; A Imtiyaz; Y Prasant; Z Mariyam; P K Julka; A Mohan; M Lone; P C Ray; A Saxena Journal: Clin Transl Oncol Date: 2014-09-26 Impact factor: 3.405
Authors: Cristiane Oliveira; Gustavo Jacob Lourenço; José Augusto Rinck-Junior; Aparecida Machado de Moraes; Carmen Silvia Passos Lima Journal: Med Oncol Date: 2017-01-03 Impact factor: 3.064
Authors: Jochen Hess; Patrick Stelmach; Andreas Eisenhardt; Herbert Rübben; Henning Reis; Kurt Werner Schmid; Hagen Sjard Bachmann Journal: J Cancer Res Clin Oncol Date: 2017-04-17 Impact factor: 4.553
Authors: Ning Zhang; Xiaoyan Li; Kai Tao; Liyu Jiang; Tingting Ma; Shi Yan; Cunzhong Yuan; Meena S Moran; Faming Liang; Bruce G Haffty; Qifeng Yang Journal: BMC Med Genet Date: 2011-04-01 Impact factor: 2.103
Authors: Young Gyu Eun; Il Ki Hong; Su Kang Kim; Hyun-Kyung Park; Sam Kwon; Dae Han Chung; Kee Hwan Kwon Journal: Clin Exp Otorhinolaryngol Date: 2011-09-06 Impact factor: 3.372